Overview

Pyridorin in Diabetic Nephropathy

Status:
Terminated

Trial end date:
2018-03-01

Target enrollment:

Participant gender:

Summary

The purpose of this study is to evaluate the safety and efficacy of oral Pyridorin 300 mg BID in reducing the rate of progression of nephropathy due to type 2 diabetes mellitus.

Phase:

Phase 3

Details

Lead Sponsor:

NephroGenex, Inc.

Collaborators:

Collaborative Study Group (CSG)
Medpace, Inc.

Treatments:

Pyridoxamine